XML 36 R24.htm IDEA: XBRL DOCUMENT v3.25.3
SUPPLEMENTAL BALANCE SHEET DETAILS (Tables)
9 Months Ended
Sep. 28, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Accounts Receivable Accounts Receivable
In millionsSeptember 28,
2025
December 29,
2024
Trade accounts receivable, gross$738 $744 
Allowance for credit losses(9)(9)
Total accounts receivable, net$729 $735 
Schedule of Inventory
Inventory
In millionsSeptember 28,
2025
December 29,
2024
Raw materials$251 $225 
Work in process418 404 
Finished goods50 31 
Inventory, gross719 660 
Inventory reserve(129)(113)
Total inventory, net$590 $547 
Schedule of Accrued Liabilities
Accrued Liabilities
In millionsSeptember 28,
2025
December 29,
2024
Contract liabilities, current portion$234 $260 
Accrued compensation expenses (1)
232 252 
Accrued taxes payable84 101 
Operating lease liabilities, current portion78 79 
Other, including warranties (2)
118 135 
Total accrued liabilities$746 $827 
_____________
(1)Includes employee separation costs related to restructuring activities.
(2)See table below for changes in the reserve for product warranties.
Schedule of Changes in Reserve for Product Warranties
Changes in the reserve for product warranties were as follows:
In millionsQ3 2025Q3 2024YTD 2025YTD 2024
Balance at beginning of period$16 $17 $18 $21 
Additions charged to cost of product revenue3 17 30 
Repairs and replacements(5)(9)(21)(35)
Balance at end of period$14 $16 $14 $16 
Schedule Of Restructuring and Related Costs
A summary of the pre-tax restructuring charges is as follows:

In millionsQ3 2025Q3 2024YTD 2025YTD 2024
Cumulative charges recorded since inception
Employee separation costs$2 $$41 $13 $101 
Asset impairment charges (1)
 —  32 146 
Other costs —  
Total restructuring charges (2)
$2 $$41 $46 $255 
_____________
(1)For YTD 2024, primarily relates to impairment of right-of-use assets and leasehold improvements for our Foster City campus.
(2)For Q3 2025, $1 million was recorded in R&D expense and $1 million in SG&A expense.
For YTD 2025, $23 million was recorded in SG&A expense, $15 million in R&D expense, with remainder in cost of revenue.
For Q3 2024, $5 million was recorded in SG&A expense and $1 million in R&D expense. For YTD 2024, $43 million was recorded in SG&A expense, $2 million in R&D expense, with remainder in cost of revenue. Charges for YTD 2024 primarily related to Core Illumina segment.
A summary of restructuring liability activity during YTD 2025 is as follows:

In millions
Employee Separation Costs (1)
Other CostsTotal
Amount recorded in accrued liabilities as of December 29, 2024
$$$
Additional expense recorded
41 — 41 
Cash payments
(39)(2)(41)
Adjustments to accrual
— — — 
Amount recorded in accrued liabilities as of September 28, 2025
$$— $
_____________
(1)It is expected that substantially all of the employee separation costs will be paid by the end of Q4 2025.